A patient presented with left chest pain and was found to have a mass. The patient underwent lung resection and was diagnosed with lung adenocarcinoma. Genetic testing revealed no driver alterations for lung cancer. The patient subsequently developed lung metastases and recurrence of the disease.

The patient was initially treated with chemotherapy consisting of carboplatin, paclitaxel, and bevacizumab. This resulted in stable disease. Subsequent treatment with docetaxel and ramucirumab also resulted in stable disease. The patient then received pemetrexed, but experienced progressive disease.

Next, the patient was treated with nivolumab, a PD-1 antibody. This immunotherapy resulted in a reduction in the lung metastases, lesion shrinkage, and a partial response. The patient was diagnosed with SMARCA4‚Äêdeficient NSCLC. The patient also had Metastatic renal cell carcinoma. The patient received nivolumab treatment. The patient also had MMR deficiency. The patient was treated with nivolumab.
